First malaria vaccine enters clinical trial in Ireland
The Royal College of Surgeons in Ireland is leading the study
The aim of the trial is to determine whether the vaccine is safe and produces an immunological response to malaria.
The Royal College of Surgeons in Ireland (RCSI) is heading the clinical trial in collaboration with the Jenner Institute at Oxford University in the UK.
The European Vaccine Initiative (EVI), a European Economic Interest Grouping (EEIG), is funding the trial.
Professor Sam McConkey, principal investigator and head of the department of International Health and Tropical Medicine at the RCSI, says malaria parasites are becoming resistant to today’s drugs, which has complicated the treatment of malaria and created a need for expensive multi-drug therapy.
‘In low income countries where malaria is endemic, expensive multi-drug therapy is often not an available treatment option so there is a need for new preventative treatments,’ he said.
Previous studies found vaccines could temporarily and partially prevent infection and clinical malaria for 18 months.
However, the new study aims to offer a vaccine that will offer long-term protection, reducing the mortality rates from malaria and moving towards eradication of the disease.
To date, 18 people have volunteered for a pre-enrolment health check-up, and 9 people have begun the study.
Further healthy adults who have not had malaria are needed and people interested in finding out more can visit the RCSI website for further information.
The first results from the trial are expected later this year.
The next step will be to establish the effectiveness of the vaccine in a phase IIa challenge model and through a phase IIb study in a country where malaria is common, with 200–300 adults.
You may also like
Trending Articles
You may also like
Research & Development
From lab to launch: transforming pharmaceutical formulation development with GEA’s CFC Lab Coater
A new generation of continuous film coating technology is giving R&D teams the speed, precision and scalability they need to take products from the laboratory to commercial production without the traditional bottlenecks
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Pharmaceutical
Ardena strengthens executive team to drive its next phase of growth
Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and commercial reach globally